caa a22 4500 605491062 CHVBK 20210128100508.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0736-9 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0736-9 Clinical results of definitive-dose (50Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer [Elektronische Daten] [Kazuki Ishikawa, Kiyoshi Nakamatsu, Osamu Shiraishi, Takushi Yasuda, Yasumasa Nishimura] Background: The clinical results of definitive-dose preoperative chemoradiotherapy (CRT) of 50Gy/25 fractions/5weeks for unresectable esophageal cancer were analyzed. Methods: Inclusion criteria were unresectable esophageal squamous cell carcinoma with T4b or mediastinal lymph nodes invading to the trachea or aorta. Radiation therapy of 50Gy/25 fractions/5weeks was combined concurrently with two courses of FP therapy (CDDP 70mg/m2+5-FU 700mg/m2/d×5days: day 1-5, day 29-33). Tumor response was evaluated 4weeks after completion of RT. Subtotal esophagectomy was planned 6-8weeks after RT. Results: Thirty patients (26 male and 4 female) aged from 50−78years (median 66) were enrolled between 2008 and 2011. The clinical stages according to the 7th edition of UICC were stages II/III/IV, 1/23/6; T1/2/3/4, 1/1/4/24; and N0/1/2/3, 3/25/1/1. All 30 patients completed RT of 50Gy/25 fractions. Initial tumor responses were 21 patients with resectable disease, 7 with unresectable disease, and 2 with progressive disease. Subtotal esophagectomy was performed in 18 (60%) of the 30 patients. Pathological complete response was obtained in five (28%) patients. There were two patients with hospitalization death after surgery (11%). Six of the 7 patients who still had unresectable disease were treated with 1-3 courses of docetaxel, CDDP and 5-FU. Three patients treated without surgery showed long-term survival. The 3-year loco-regional control rate and the 3-year overall survival rate for the 30 patients were 70 and 49%, respectively. Conclusions: Definitive-dose preoperative CRT was feasible, and is a promising treatment strategy for unresectable esophageal cancer. Japan Society of Clinical Oncology, 2014 Unresectable esophageal cancer nationallicence Preoperative treatment nationallicence Chemoradiotherapy nationallicence Ishikawa Kazuki Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut Nakamatsu Kiyoshi Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut Shiraishi Osamu Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan aut Yasuda Takushi Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan aut Nishimura Yasumasa Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 531-537 1341-9625 20:3<531 2015 20 10147 https://doi.org/10.1007/s10147-014-0736-9 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0736-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ishikawa Kazuki Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut NATIONALLICENCE 700 1- Nakamatsu Kiyoshi Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut NATIONALLICENCE 700 1- Shiraishi Osamu Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Yasuda Takushi Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Nishimura Yasumasa Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 531-537 1341-9625 20:3<531 2015 20 10147